Product Information
METHYLPHENIDATE ER 40 MG CAP is a generic product labeled by Rhodes Pharmaceuticals L.P., priced at $4.2291 per EA under NDC 42858007945. Its NADAC has been published 66 times since Apr 17, 2024.
FDA first approved this application on Apr 17, 2015. Its Orange Book therapeutic-equivalence code is AB3 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
40 mg/1
Manufacturer
Rhodes Pharmaceuticals L.P.NDC
42858007945
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
12/18/2024
Active Ingredients
METHYLPHENIDATE HYDROCHLORIDEApproval Type
Authorized Generic (NDA)
FDA Application
NDA205831FDA Approved
4/17/2015
TE Code
AB3
On Market Since
4/1/2020
Pharmacological Classes
Price Statistics
The NADAC for METHYLPHENIDATE ER 40 MG CAP has been published 66 times since Apr 17, 2024, and over the history we have for it it has risen 2.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $4.2291 per EA |
|---|---|
| All-time high | $4.2540 (Jul 10, 2024) |
| All-time low | $3.9047 (Sep 18, 2024) |
| Median price | $4.2291 |
| Average price | $4.1770 |
| Largest weekly change | +8.3% (Oct 23, 2024) |
| Weeks tracked | 66 |
| Tracking since | Apr 17, 2024 |
1W
N/A
1M
N/A
3M
N/A
6M
N/A
1Y
N/A
3Y
N/A
5Y
N/A
All
+2.5%
Last surveyed Jul 16, 2025 — this NDC no longer appears in the current weekly NADAC file.
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 66% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rhodes Pharmaceuticals L.P. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Methylphenidate Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Central Nervous System Stimulant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of METHYLPHENIDATE ER 40 MG CAP?
The current National Average Drug Acquisition Cost (NADAC) for METHYLPHENIDATE ER 40 MG CAP, manufactured by Rhodes Pharmaceuticals L.P., is $4.2291 per EA (NDC 42858007945), effective Jul 16, 2025.
How has the price of METHYLPHENIDATE ER 40 MG CAP changed over time?
Over the history we have for it, the NADAC for METHYLPHENIDATE ER 40 MG CAP has risen 2.5%. It has been tracked across 66 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for METHYLPHENIDATE ER 40 MG CAP?
Since Apr 17, 2024, the NADAC for METHYLPHENIDATE ER 40 MG CAP has ranged from a low of $3.9047 (Sep 18, 2024) to a high of $4.2540 (Jul 10, 2024), with a median of $4.2291 per EA.
Are there cheaper alternatives to METHYLPHENIDATE ER 40 MG CAP?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, METHYLPHENIDATE ER(CD) 40 MG CP, is $1.4414 per EA — about 66% below METHYLPHENIDATE ER 40 MG CAP.
Who manufactures METHYLPHENIDATE ER 40 MG CAP?
METHYLPHENIDATE ER 40 MG CAP (NDC 42858007945) is labeled by Rhodes Pharmaceuticals L.P., and CMS classifies it as a generic product.